Accuray to Unveil Latest Innovations at Estro

- Next generation delivery system designed for increased throughput, higher reliability andease of serviceability  Accuray Incorporated (NASDAQ: ARAY) announced the company will showcase its portfolio of radiation therapy delivery systems and software solutions at the annual European Society for Therapeutic Radiology and Oncology (ESTRO) meeting being held in Turin, ItalyApril 29 - May 3, 2016. Meeting attendees are invited to attend the unveiling of the company's newest innovation, the Radixact™ Treatment Delivery System*, at Accuray booth #1300 on Saturday, April 30 at 10:10 a.m.      (Logo: http://photos.prnewswire.com/prnh/20151126/291246LOGO )      (Photo: http://photos.prnewswire.com/prnh/20160427/360580 ) The Radixact System is the next generation TomoTherapy® platform. The Radixact System, in combination with the Precision™ Treatment Planning System* and iDMS™ Data Management System*, is intended to provide clinicians with a foundation for expanded clinical capabilities to help ensure the platform will be highly utilized for years to come, while driving excellence in outcomes across a wide range of patient cases. The Radixact technology is being designed to enable faster image acquisition and treatment delivery. The high output, compact linear accelerator is capable of producing a dose rate of 1,000 MU per minute, and imaging speed will increase. "The addition of the Radixact technology to the Accuray CyberKnife® System and TomoTherapy® System product portfolio reinforces the company's commitment to bringing to market innovative radiation therapy solutions that make a difference in the lives of people with cancer," said Lionel Hadjadjeba who serves as corporate senior vice president, and president worldwide commercial operations at Accuray. "For more than two decades, the company has introduced technology which has helped drive the evolution of radiotherapy treatments. We are dedicated to providing our customers with more powerful, more flexible options that make precise radiation treatment available to more patients." Additional meeting highlights and events: The InCise MLC is the world's first MLC to be available on a robotic platform, the CyberKnife M6™ System. The combination of delivery system and MLC is demonstrating to be an extremely efficient delivery system, significantly reducing treatment times while maintaining high standards of conformality and dose distribution for a broad range of clinical cases. Accelerated treatment time means greater throughput for the hospital and less time on the treatment couch for patients. Accuray and RaySearch have expanded their existing relationship which will lead to the integration of treatment planning support for the TomoTherapy® and CyberKnife® Systems in the RayStation® treatment planning system. For the first time, clinics will have access to an advanced, integrated treatment planning system for Accuray treatment delivery systems and conventional linear accelerators, getting unprecedented choice of radiation therapy planning and treatment delivery systems to best meet patients' needs. Björn Hårdemark, Deputy CEO at RaySearch, will present a preview of the system in the Accuray booth on Sunday, May 1, 2016 from 3:40 p.m. to 4:00 p.m. Accuray Exchange in Radiation Oncology (AERO™) Academy sessions on an extensive range of topics will be held daily throughout the meeting. Accuray hosts these educational events to provide clinicians with the opportunity to engage in interactive discussions on the real-world use of Accuray technologies. For more information, please visit: http://www.accuray.com/estro35/. *The Radixact™ Treatment Delivery System, Precision™ Treatment Planning System and iDMS™ Data Management System are pending US FDA 510(k) clearance and not available for sale. These products may also be subject to international regulatory approval or licensing processes such that the availability of these products may vary according to geographical location.  About Accuray  Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit http://www.accuray.com. Safe Harbor Statement  Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes, anticipated regulatory approvals and launches of new products, market uptake of recently launched products, market adoption of the company's products and Accuray's leadership position radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 28, 2015, the company's reports on Form 10-Q, filed on November 5, 2015 and February 1, 2016, and the company's other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.